featured
Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis
J. Clin. Oncol 2020 Jul 30;[EPub Ahead of Print], E Kastritis, X Leleu, B Arnulf, E Zamagni, MT Cibeira, F Kwok, P Mollee, R Hájek, P Moreau, A Jaccard, SO Schönland, R Filshie, E Nicolas-Virelizier, B Augustson, MV Mateos, A Wechalekar, E Hachulla, P Milani, MA Dimopoulos, JP Fermand, A Foli, M Gavriatopoulou, C Klersy, A Palumbo, P Sonneveld, HE Johnsen, G Merlini, G PalladiniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.